Note: Descriptions are shown in the official language in which they were submitted.
WO 2021/050580
PCT/US2020/049986
CRYSTALLINE FORM OF A MULTI-TYROSINE
KINASE INHIBITOR, METHOD OF PREPARATION, AND USE THEREOF
FIELD OF THE INVENTION
[001] The present invention relates to crystalline forms of a multi-tyrosine
kinase inhibitor. In
particular, the present invention relates to a crystalline form of the multi--
tyrosine kinase inhibitor
N-(3-fluoro-4-42-(5-(((2-methoxyethyl)amino)methyl)pyridin-2-y1)thieno[3,2-
b]pyridin-7-
yfloxy)pheny1)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,
pharmaceutical
compositions comprising the crystalline form, processes for preparing the
crystalline form, and
methods of use thereof
BACKGROUND OF THE INVENTION
[002] International publication No. W02009/026717A disclosed compounds with
the
inhibition activities of multiple protein tyrosine kinases, for example, the
inhibition activities of
VEGF receptor kinase and HGF receptor kinase. In particular, disclosed N-(3-
fluoro-442-(5-
(((2-methoxyethyDamino)methyl)pyridin-2-yOthieno[3,2-b]pyridin-7-
yfloxy)phenyl)-N-(4-
fluorophenyl)cyclopropane-1,1-dicarboxamide (Compound 1) is a multi-tyrosine
kinase
inhibitor with demonstrated potent inhibition of a closely related spectrum of
tyrosine kinases,
including RET, CBL, CIIR4q12, DDR and Trk, which are key regulators of
signaling pathways
that lead to cell growth, survival and tumor progression.
[003]
HiNH
N
N
0 0 011
0
S F
\
\ I
NH -N
Compound 1
[004] Compound 1 shows tumor regression in multiple human xenograft tumor
models in
mice, and is presently in human clinical trials as a monotherapy as well as in
combination for
1
CA 03150267 2022-3-5
WO 2021/050580
PCT/US2020/049986
treating a wide range of solid tumors. Compound 1 is presently in Phase 1
clinical trial for
patients with advanced cancer, in Phase 2 studies for patients with advanced
liposarcoma and
non-small cell lung cancer (NSCLC).
[005] The small scale chemical synthesis of the amorphous Compound 1 had been
disclosed in
the Example 52 (compound 147) of W02009/026717A, however, in order to prepare
the API of
Compound 1 with high quality and in large quantity, crystalline forms of
Compound 1 would
be normally needed so the process impurities could be purged out by
recrystallization.
Practically, it is difficult to predict with confidence which crystalline form
of a particular
compound will be stable, reproducible, and suitable for phamaceutical
processing. It is even
more difficult to predict whether or not a particular crystalline solid state
form will be produced
with the desired physical properties for pharmaceutical formulations.
[006] For all the foregoing reasons, there is a great need to produce
crystalline forms of
Compound 1 that provide manufacturing improvements of the pharmaceutical
composition.
The present invention advantageously addresses one or more of these needs.
SUMMARY OF THE INVENTION
[007] The present application discloses an invention to address the foregoing
challenges and
need by providing crystalline forms thereof The inventors of present invention
have
unexpectedly found that it was very difficult to obtain a single phase of
crystalline form for N-(3-
fluoro-4-02-(5-(((2-methoxyethyDamino)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-
7-
yfloxy)pheny1)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (hereinafter
referred to as
Compound 1). After conducting systematic solid form screening studies with
great effort, the
inventors of present invention obtained several crystalline materials of
Compound 1, Materials
A through L, and Forms C, D and H. However, only three crystalline forms
(Forms C, D and H)
existed with phase uniformity, all other forms were composed of disordered
mutiple phases.
Finaly, the inventors of present invention found only Form D has superior
physical properties
suitable for pharmaceutical formulations and can be manufactured in large
commercial scales
with high quality and good reproducibility.
[008] In first aspect of the invention, provided herein is a crystalline form
of Compound 1.
2
CA 03150267 2022-3-5
WO 2021/050580
PCT/US2020/049986
[009] In one embodiment, the crystalline form of Compound 1 is designated as
Form C, Form
D and Form H.
[0010] In one embodiment, the crystalline form of Compound 1 is designated as
Form D, which
has an X-ray powder diffraction pattern (XRPD) comprising diffraction peaks
having 020 angle
values independently selected from the group consisting of 7.8+0.2 , 14.3+02
and 17.2+0.2 .
[0011] In one embodiment, the Crystalline Form of Compound 1 (Form D) can be a
single
crystal.
[0012] In one embodiment, the crystalline form of Compound 1 is designated as
Form C.
[0013] In one embodiment, the crystalline form of Compound 1 is designated as
Form H.
[0014] In another embodiment, the crystalline form of Compound 1 has an XRPD
pattern
substantially as shown in Figure 1A, Figure 2A(1), Figure 3B, Figure 3C or
Figure 3D.
[0015] In second aspect of the invention, pharmaceutical compositions are
provided for use in
the methods comprising a therapeutically effective amount of a crystalline
form of Compound 1,
and pharmaceutically acceptable excipient. In one embodiment, the crystalline
form of
Compound 1 is selected from Form C, Form D and Form H.
[0016] In third aspect of the invention, provided herein are methods for
inhibiting multi-tyrosine
kinase activity in a cell, comprising contacting the cell in which inhibition
of multi-tyrosine
kinase activity is desired with a therapeutically effective amount of a
crystalline form of
Compound 1. In one embodiment, the crystalline form of Compound 1 is selected
from Form
C, Form D and Form H.
[0017] In fouth aspect of the invention, provided herein are methods of
treating cancer in a
subject in need thereof, comprising administering to the subject a
therapeutically effective
amount of a crystalline form of Compound 1. In one embodiment, the cancer is a
multi-tyrosine
kinase-associated cancer. In one embodiment, the multi-tyrosine kinase-
associated cancer is
lung cancer, including non-small cell lung cancer (NSCLC). In one embodiment,
the crystalline
form of Compound 1 is selected from Form C, Form D and Form H.
3
CA 03150267 2022-3-5
WO 2021/050580
PCT/US2020/049986
[0018] In fifth aspect of the invention, provided herein are processes for the
preparation of a
crystalline form of Compound 1. In one embodiment, the crystalline form of
Compound 1 is
selected from Form C, Form D and Form H.
BRIEF DESCRIPTION OF THE FIGURES
[0019] Figure 1A illustrates an X-ray powder diffraction (XRPD) pattern of
Crystalline Form D
of Compound 1 (Compound 1 Form D) prepared according to Example 2A.
[0020] Figure 1B illustrates a differential scanning calorimetry (DSC) profile
of Crystalline
Form D of Compound 1 (Compound 1 Form D) prepared according to Example 2K
[0021] Figure 2A: Figure 2A(1) illustrates the simulated X-ray powder
diffraction (XRPD)
pattern of Crystalline Form D of Compound 1 (Compound 1 Form D, a single
crystal) prepared
according to Example 213; Figure 2A(2) illustrates overlaid spectra of
simulated (single crystal),
experimental XRPD patterns of Crystalline Form D of Compound 1 (Compound 1
Form D)
prepared according to Example 2B.
[0022] Figure 2B illustrates the crystal structure of Crystalline Form D of
Compound 1
(Compound 1 Form D, a single crystal) prepared according to Example 2B.
[0023] Figure 2C illustrates the crystal packing of Crystalline Form D of
Compound 1
(Compound 1 Form D, a single crystal) prepared according to Example 2B.
[0024] Figure 3A illustrates an X-ray powder diffraction (XRPD) patterns of
Crystalline Forms
C, D and H of Compound 1 (Compound 1 Forms C, D and H) in Example 3.
[0025] Figure 3B illustrates an indexing solution for X-ray powder diffraction
(XRPD) patterns
of Crystalline Form C of Compound 1 (Compound 1 Form C) in Example 3.
[0026] Figure 3C illustrates an indexing solution for X-ray powder diffraction
(XRPD) patterns
of Crystalline Form D of Compound 1 (Compound 1 Form D) in Example 3.
[0027] Figure 3D illustrates an indexing solution for X-ray powder diffraction
(XRPD) patterns
of Crystalline Form H of Compound 1 (Compound 1 Form H) in Example 3.
4
CA 03150267 2022-3-5
WO 2021/050580
PCT/US2020/049986
[0028] Figure 3E the X-ray powder diffraction (XRPD) patterns of Materials A
Through L of
Compound 1 (Compound 1 Materials A Through L) in Example 3.
[0029] Figure 3F illustrates TGA and DSC Thermograms for Crystalline Form D of
Compound 1 (Compound 1 Form D) produced in acetone in Example 3. Sample was in
vacuum
dried at ¨40 C for ¨2.5 hours.
[0030] Figure 3G illustrates an X-ray powder diffraction (XRPD) patterns of
Crystalline
Materials B (containing Material 0), 0 and A of Compound 1 in Example 3.
DETAILED DESCRIPTION OF THE INVENTION
[0031] The present invention relates to crystalline forms of Compound 1. In
particular, the
present invention relates to a crystalline form selected from Form C, Form D
or Form H of
Compound 1, pharmaceutical compositions comprising the crystalline form,
processes for
preparing the crystalline form and methods of use therefor.
[0032] In one embodiment, the crystalline form of Compound 1 is designated as
Form C, Form
D and Form H.
[0033] In one embodiment, the crystalline form of Compound 1 is designated as
Form D, which
has an X-ray powder diffraction pattern (XRPD) comprising diffraction peaks
having '20 angle
values independently selected from the group consisting of 7.8+0.2 , 14.3+0.2'
and 17.2+0.2".
[0034] In one embodiment, the crystalline form of Compound 1 is designated as
Form D, which
has an X-ray powder diffraction pattern (XRPD) comprising diffraction peaks
having 020 angle
values independently selected from the group consisting of 7.8- 0.2 ,
14.3+0.2', 17.2-+0.2" and
21.7+0.2 .
[0035] In one embodiment, the crystalline form of Compound 1 is designated as
Form D, which
has an X-ray powder diffraction pattern (XRPD) comprising diffraction peaks
having 020 angle
values independently selected from the group consisting of 7,8+0.2 , 14.3+0.2
, 17.2+0.2 ,
21.7+0.2 and 26.4+02 .
CA 03150267 2022-3-5
WO 2021/050580
PCT/US2020/049986
[0036] In another embodiment, Form D has an X-ray powder diffraction pattern
comprising
diffraction peaks having '20 angle values independently selected from the
group consisting of
7.8+0.2 , 14.3+0.2', 16.6+0.2 , 17.2+0.2 , 19.3+0.2 , 21.7+0.2' and 26.4+0.2".
[0037] In another embodiment, Form D has an X-ray powder diffraction pattern
comprising
diffraction peaks having 020 angle values independently selected from the
group consisting of
7.8+0.2', 143+0.2', 16.6+0.2 , 17.2+0.2 , 19,3+0.2 , 21.7+0.2 , 233+0.2 ,
26.4+0.2 and
28.2+0.2 .
[0038] In another embodiment, Form D has an X-ray powder diffraction pattern
comprising
diffraction peaks having '20 angle values independently selected from the
group consisting of
6.50+0.2 , 7.8+0.2 , 14.3+0.2', 16.6+0.2', 17.2+0_2 , 19.3+0_2 , 21.7+0.2 ,
23.3+0.2 ,
251+0.2 , 26.4+0.2 and 28.2+0.20.
[0039] In another embodiment, Form D has an XRPD pattern substantially as
shown in Figure
1A.
[0040] In another embodiment, Form D is characterized by having a broad small
endothertn with
a peak maximum at approximately 57 C to 62 C (onset ¨20 C to 22 C) followed by
a sharp
endotherm with a peak maximum at approximately 180 C (onset -178 C) by
differential
scanning calorimetry (DSC). In another embodiment, Form D has a DSC thermogram
substantially as shown in Figure 1B.
[0041] In one embodiment, Form D of Compound 1 can be a single crystal, which
has a crystal
structural data is summarized in Table 113. As shown in Figure 2B, the single
crystal structure of
Compound 1 Form D is in the P-1 space group and the triclinic crystal system.
The terminal
long alkyl chain is found to have large ellipsoids, indicating high mobility
with disordered atoms.
And some channels can be found around the alkyl chain in crystal packing, see
Figure 2C.
[0042] Table 1B. Crystal Data and Structure Refinement for Compound 1 Form D
(a
Single Crystal)
Empirical formula
C33H29F2N504S
Formula weight
629.67
Temperature/K
179.99(10)
6
CA 03150267 2022- 3- 5
WO 2021/050580
PCT/US2020/049986
Crystal system
triclinic
Space group
P-1
a/A
9.4563(5)
b/A
12.3432(5)
c/A
14.4775(6)
a?
67.575(4)
fir
83.080(4)
7i
80.099(4)
Volume/A'
1535.98(13)
2
peakg/an3
1.361
p/mm-I
0.164
F(000)
656.0
Crystal size/mm3
0.22 x 0.16 x 0.12
Radiation
Mo Ka (A = 0.71073)
20 range for data collection?
5.184 to 54.958
Index ranges -11
<h< 12 -15 <k< 16 -18 </< 18
Reflections collected
19644
Independent reflections
7025 [Rini = 0.0232, Rsigina = 0.0321]
Data/restraints/parameters
7025/312/442
Goodness-of-fit on F2
1.036
Final R indexes [I>=2o- (I)]
Ri = 0.0587, wR2 = 0.1494
Final R indexes [all data]
R1= 0.0780, wR2 = 0.1599
Largest diff. peak/hole / c A-3
0.96/-0.45
[0043] In another embodiment, Form D has an XRPD pattern substantially as
shown in Figure
2A(1).
[0044] In one embodiment, Form D has an XRPD pattern substantially as shown in
Figure 3C.
In another embodiment, Form D has an DSC and / or TGA substantially as shown
in Figure 3F.
7
CA 03150267 2022-3-5
WO 2021/050580
PCT/US2020/049986
[0045] In one embodiment, the crystalline form of Compound 1 is designated as
Form C. In
another embodiment, Form C has an XRPD pattern substantially as shown in
Figure 3B.
[0046] In one embodiment, the crystalline form of Compound 1 is designated as
Form H In
another embodiment, Form H has an XRPD pattern substantially as shown in
Figure 3D.
[0047] In one embodiment, the crystalline forms of the present invention are
at least 40%, 50%,
60%, 70%, 80%, 90% or 95% purified crystalline form.
[0048] In second aspect of the invention, pharmaceutical compositions are
provided for use in
the methods comprising a therapeutically effective amount of a crystalline
form of Compound 1,
and pharmaceutically acceptable excipient. In one embodiment, the crystalline
form of
Compound 1 is selected from Form C, Form D and Form H. In another embodiment,
the
crystalline form of Compound 1 is Form D.
[0049] The crystalline forms of Compound 1 may be formulated by any method
well known in
the art and may be prepared for administration by any route, including,
without limitation,
parenteral, oral, sublingual, transdermal, topical, intranasal, intratracheal,
or intrarectal. In certain
embodiments, the crystalline form of Compound 1 is administered intravenously
in a hospital
setting. In one embodiment, administration may be by the oral route.
[0050] The characteristics of the carrier will depend on the route of
administration. As used
herein, the term "pharmaceutically acceptable" means a non-toxic material that
is compatible
with a biological system such as a cell, cell culture, tissue, or organism,
and that does not
interfere with the effectiveness of the biological activity of the active
ingredient(s). Thus,
compositions may contain, in addition to the inhibitor, diluents, fillers,
salts, buffers, stabilizers,
solubilizers, and other materials well known in the art. The preparation of
pharmaceutically
acceptable formulations is described in, e.g., Remington's Pharmaceutical
Sciences, 18th Edition,
ed. A. Gennaro, Mack Publishing Co., Easton, Pa., 1990.
[0051] In one embodiment, the pharmaceutical compositons of the present
invention contain
95% of a crystalline form of Compound 1. In another embodiment, the
pharmaceutical
compositons of the present invention contain at least 95% of a crystalline
form of Compound 1.
In another embodiment, the pharmaceutical compositons of the present invention
contain at least
8
CA 03150267 2022-3-5
WO 2021/050580
PCT/US2020/049986
90% of the crystalline form of Compound 1. In another embodiment, the
pharmaceutical
compositons of the present invention contain at least 80% of the crystalline
form of Compound
1. In another embodiments, the pharmaceutical compositons of the present
invention contain at
least 70% of the crystalline form of Compound 1. In another embodiment, the
pharmaceutical
compositons of the present invention contain at least 60% of the crystalline
form of Compound
1. In another embodiment, the pharmaceutical compositons of the present
invention contain at
least 50% of the crystalline form of Compound 1.
[0052] The pharmaceutical compositions comprising a crystalline form of
Compound 1 may be
used in the methods of use described herein.
[0053] In third aspect of the invention, provided herein are methods for
inhibiting multi-tyrosine
kinase activity in a cell, comprising contacting the cell in which inhibition
of multi-tyrosine
kinase activity is desired with a therapeutically effective amount of a
crystalline form of
Compound 1. In one embodiment, the crystalline form of Compound 1 is selected
from Form
C, Form D and Form H. In another embodiment, the crystalline form of Compound
1 is Form
D.
[0054] In fourth aspect of the invention, provided herein are methods of
treating cancer in a
subject in need thereof, comprising administering to the subject a
therapeutically effective
amount of a crystalline form of Compound 1.
[0055] The compositions and methods provided herein may be used for the
treatment of a wide
variety of cancers. Examples of particular types of cancer include, but are
not limited to, breast
cancer, lung cancer, including non-small cell lung cancer (NSCLC), colon
cancer, rectal cancer,
bladder (urothelial) cancer, prostate cancer, leukemia, kidney (renal) cancer,
glioma, sarcoma,
including leiomyosarcoma, liver (hepatocellular) cancer, ovarian cancer and
gastric cancer.
[0056] In one embodiment, the cancer is a multi-tyrosine kinase-associated
cancer.
[0057] In one embodiment, the multi-tyrosine kinase-associated cancer is
NSCLC, liposarcoma,
urothelial carcinoma, and cancer of the oral cavity. In one embodiment, the
multi-tyrosine
kinase-associated cancer is non-small cell lung cancer (NSCLC).
9
CA 03150267 2022-3-5
WO 2021/050580
PCT/US2020/049986
[0058] The active compound is included in the pharmaceutically acceptable
carrier or diluent in
an amount sufficient to deliver to a patient a therapeutically effective
amount without causing
serious toxic effects in the patient treated. In one embodiment, a dose of the
active compound
for all of the above-mentioned conditions is in the range from about 0.6 to
1800 mg per day, for
example 5 to 1000 mg per day, and as a further example 50 to 200 mg of the
recipient per day.
In one embodiment, the active compound is administered at a dose of 150 mg,
preferably orally,
and preferably in a continuous 21 day cycle. A typical topical dosage will
range from 0.01-3%
wt/wt in a suitable carrier. The effective dosage range of the
pharmaceutically acceptable
derivatives can be calculated based on the weight of the parent compound to be
delivered. If the
derivative exhibits activity in itself, the effective dosage can be estimated
as above using the
weight of the derivative, or by other means known to those skilled in the art.
[0059] In some embodiments of any of the methods described herein, before
treatment with the
compositions or methods of the invention, the patient was treated with one or
more of a
chemotherapy, a targeted anticancer agent, radiation therapy, and surgery, and
optionally, the prior
treatment was unsuccessful; and/or the patient has been administered surgery
and optionally, the
surgery was unsuccessful; and/or the patient has been treated with a platinum-
based
chemotherapeutic agent, and optionally, the patient has been previously
determined to be non-
responsive to treatment with the platinum-based chemotherapeutic agent; and/or
the patient has
been treated with a kinase inhibitor, and optionally, the prior treatment with
the kinase inhibitor
was unsuccessful; and/or the patient was treated with one or more other
therapeutic agent(s).
[0060] In one embodiment, the multi-tyrosine kinase inhibitor is orally
administered once daily.
In one embodiment, the crystalline form of Compound 1 is orally administered
twice daily. In
one embodiment, the crystalline form of Compound 1 is orally administered once
daily. In one
embodiment, the crystalline form of Compound 1 is selected from Form C, Form D
Form H. In
another embodiment, the crystalline form of Compound 1 is Form D.
[0061] One skilled in the art will recognize that, both in vivo and in vitro
trials using suitable,
known and generally accepted cell and/or animal models are predictive of the
ability of a test
compound of the combination or the combination to treat or prevent a given
disorder.
CA 03150267 2022-3-5
WO 2021/050580
PCT/US2020/049986
[0062] One skilled in the art will further recognize that human clinical
trials including first-in-
human, dose ranging and efficacy trials, in healthy patients and/or those
suffering from a given
disorder, may be completed according to methods well known in the clinical and
medical arts.
[0063] In fifth aspect of the invention, provided herein is a process for the
preparation of
Crystalline Form D of N-(3-fluoro-4-((2-(5-(((2-
methoxyethyDamino)methyl)pytidin-2-
yl)thieno[3,2-b]pyridin-7-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-
dicarboxamide
(Compound 1), comprising any one of the following procedures:
1) dissolving N-(3-fluoro-4-02-(5-(((2-methoxyethyDamino)methyl)pyridin-2-
y1)thieno[3,2-b]pyridin-7-yl)oxy)phenyl)-N-(4-fluorophenypcyclopropane-1,1-
dicarboxamide in
acetone, heating to reflux, cooling with stiring, to obtain Form D;
2) dissolving N-(3-fluoro-4-02-(5-(((2-methoxyethyl)amino)methyppyridin-2-
yl)thieno[3,2-b]pyridin-7-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-
dicarboxamide,
Form D as crystal seed in acetone, heating to reflux, cooling with stiring, to
obtain Form D;
3) triturating N-(3-fluoro-44(2-(54((2-methoxyethyDamino)methyl)pyridin-2-
y1)thienoP,2-
b]pyridin-7-yl)oxy)pheny1)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide in
an organic
solvent at ambient temperature, filtering the slurries, replacing the organic
solvent with fresh
organic solvent, to obtain Form D, wherein the organic solvent is selected
from acetone, ACN,
CHC13, MTBE, DMFõ Et0H, Nitromethane, or a mixture thereof;
4) dissolving N-(3-fluoro-4-02-(5-(((2-methoxyethyDamino)methyppyridin-2-
yl)thieno[3,2-b]pyridin-7-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-
dicarboxamide in
THF, evaporating, dissolving in Et0Ac, precipitating, to obtain Form D; and,
5) triturating N-(3-fluoro-442-(5-00-methoxyethyDamino)methyl)pyridin-2-
y1)thieno[3,2-
b]pyridin-7-ypoxy)pheny1)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide in
IPA at ¨40
C, filtering the slurries, replacing the IPA with fresh IPA, to obtain Form D.
[0064] In one embodiment, the process for the preparation of Crystalline Form
D of N-(3-fluoro-
44(2-(5-(((2-methoxyethyl)amino)methyppyridin-2-yOthieno[3,2-b]pyridin-7-
ypoxy)phenyl)-N-
(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, comprising any one of the
following
procedures:
1) dissolving N-(3-fluoro-4-02-(5-(((2-methoxyethyl)amino)methyl)pyridin-2-
yl)thieno[3,2-b]pyridin-7-y0oxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-
dicarboxamide
11
CA 03150267 2022-3-5
WO 2021/050580
PCT/US2020/049986
Form D as crystal seed in acetone, heating to reflux, cooling with stiring, to
obtain Form D,
heating to reflux for 1-2 h, cooling to an internal temperature of 20+5 C for
at least 24 h,
filtering and washing the filter cake with acetone, drying under vacuum at
=1/245 C, to obtain the
Form D;
2) triturating N-(3-fluoro-442-(5-0(2-methoxyethypamino)methyppyridin-2-
y1)thieno[3,2-b]pyridin-7-ynoxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-
dicarboxamide in
an organic solvent at ambient temperature, filtering the slurries after
approximately 24 hours,
replacing the organic solvent with fresh orgianic solvent, to obtain Form D,
wherein the organic
solvent is selected from acetone, ACN, CHC13, MTBE, DMFõ Et0H, nitromethane,
or a mixture
thereof;
3) dissolving N-(3-fluoro-44(2-(5-(((2-methoxyethyDamino)methyppyridin-2-
yl)thieno[3,2-
b]pyridin-7-yl)oxy)pheny1)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide in
THE,
evaporating, dissolving in Et0Ac, stirring, precipitating, to obtain Form D;
4) triturating N-(3-fluoro-4-02-(54(2-methoxyethyl)amino)methyl)pyridin-2-
yOthieno[3,2-
b]pyridin-7-ypoxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide in
IPA at ¨40
C, filtering the slurries after approximately 24 hours, replacing the IPA with
fresh IPA, to obtain
Form D.
[0065] In another embodiment, the organic solvent is selected from CHC13/MTBE
(50/50, v/v)
and DMF/ACN (30/70, v/v). In another embodiment, the resulting slurries were
triturated for up
to ¨2.5 weeks.
DEFINITIONS
[0066] Unless defined otherwise, all technical and scientific terms used
herein have the same
meaning as is commonly understood by one of skill in the art to which this
invention belongs.
All patents, patent applications, and publications referred to herein are
incorporated by reference_
[0067] As used herein, "Compound 1" refers to N-(3-fluoro-4-02-(5-(((2-
methoxyethyDamino)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-y0oxy)pheny1)-N-
(4-
fluorophenyl)cyclopropane-1,1-dicarboxamide.
12
CA 03150267 2022-3-5
WO 2021/050580
PCT/US2020/049986
[0068] As used herein, a "crystalline form of Compound 1" refers to the
crystalline form of
N-(3-fluoro-4-02-(5-(((2-methoxyethyl)amino)methyppyridin-2-ypthieno[3,2-
b]pyridin-7-
yfloxy)pheny1)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide.
[0069] Materials exhibiting unique crystalline XRPD patterns are assigned
sequential Roman
alphabetical characters as the default designation, if no other character
types already pertain to
the compound. The designation is tentatively associated with the term
'Material until the phase
purity obtained through indexing of the XRPD pattern, and chemical identity
obtained through
proton nuclear magnetic resonance spectroscopy (11-1NMR) is determined. When
the
characterization data are consistent with a unique crystalline form composed
of a single phase
Materials are further designated as "Forms" with the same letter designation
(i.e., Material C
becomes Form C). In the present invention, the XRPD pattern of a "Form" of the
compound
can be successfully indexed. But, the XRPD pattern of a "Material" cannot be
indexed, the
"Material" is a crystalline material with some degree of disorder, or a
mixture.
[0070] As used herein, the term "Form C" or "Crystalline Form C" when used
alone refers to
Crystalline Form C of N-(3-fluoro-4-02-(5-(((2-
methoxyethypamino)methyl)pyridin-2-
yl)thieno[3,2-b]pyridin-7-yl)oxy)pheny1)-N-(4-fluorophenyl)cyclopropane-1,1-
dicarboxamide.
And, the terms "Form D" or "Crystalline Form D" have similar meaning as that
of "Form C"
or "Crystalline Form C".
[0071] A "multi-tyrosine kinase-associated disease or disorder" as used herein
refers to
diseases or disorders associated with or mediated by oncogenic driver
mutations in RET, CBL,
CHR4q12, DDR and/or Trk.
[0072] As used herein, the term "subject," "individual," or "patient," used
interchangeably,
refers to any animal, including mammals such as mice, rats, other rodents,
rabbits, dogs, cats,
swine, cattle, sheep, horses, primates, and humans. In some embodiments, the
patient is a human.
In some embodiments, the subject has experienced and/or exhibited at least one
symptom of the
disease or disorder to be treated and/or prevented. In some embodiments, the
subject is
suspected of having a multi-tyrosine kinase-associated cancer.
[0073] As used herein, a "therapeutically effective amount" of a crystalline
form of
Compound 1 is an amount that is sufficient to ameliorate, or in some manner
reduce a symptom
13
CA 03150267 2022-3-5
WO 2021/050580
PCT/US2020/049986
or stop or reverse progression of a condition, or negatively modulate or
inhibit the activity of a
mutli-tyrosine kinase. Such amount may be administered as a single dosage or
may be
administered according to a regimen, whereby it is effective.
[0074] As used herein, "treatment" means any manner in which the symptoms or
pathology of a
condition, disorder or disease are ameliorated or otherwise beneficially
altered. Treatment also
encompasses any pharmaceutical use of the compositions herein,
[0075] As used herein, amelioration of the symptoms of a particular disorder
by administration
of a particular pharmaceutical composition refers to any lessening whether
permanent or
temporary, lasting or transient that can be attributed to or associated with
administration of the
composition.
[0076] As used herein, the term "about" when used to modify a numerically
defined parameter
(e.g., the dose of a crystalline form of Compound 1 detailed herein or a
pharmaceutically
acceptable salt thereof, or the length of treatment time described herein)
means that the
parameter may vary by as much as 10% below or above the stated numerical value
for that
parameter. For example, a dose of about 5 mg/kg may vary between 4.5 mg/kg and
5.5 mg/kg.
"About" when used at the beginning of a listing of parameters is meant to
modify each
parameter. For example, about 0.5 mg, 0.75 mg or 1.0 mg means about 0.5 mg,
about 0.75 mg
or about 1.0 mg, Likewise, about 5% or more, 10% or more, 15% or more, 20% or
more, and
25% or more means about 5% or more, about 10% or more, about 15% or more,
about 20% or
more, and about 25% or more.
[0077] As used herein, the term "about" when used in reference to XRPD peak
positions refers
to the inherent variability of peaks depending on the calibrtation of the
instrument, processes
used to prepare the crystalline forms of the present invention, age of the
crystalline forms and the
type of instrument used in the analysis. The variability of the
instrumentation used for XRPD
analysis was about Jz 0.2 020.
[0078] As used herein, the term "about" when used in reference to DSC
endothermic peak onset
refers to the inherent variability of peaks depending on the calibrtation of
the instrument, method
used to prepare the samples of the present invention, and the type of
instrument used in the
analysis. The variability of the instrumentation used for DSC analysis was
about 2 C.
14
CA 03150267 2022-3-5
WO 2021/050580
PCT/U52020/049986
GENERAL METHODS
[0079] The general methods outlined below were used in the exemplified
Examples, unless
otherwise noted.
[0080] I. Crystallization Techniques
[0081] Crystalline forms of the present invention may be prepared using a
variety of methods
well known to those skilled in the art including crystallization or
recrystallization from a suitable
solvent or by sublimation. A wide variety of techniques may be employed,
including those in the
exemplified Examples, for crystallization or recrystallization including
evaporation of a water-
miscible or a water-immiscible solvent, crystal seeding in a supersaturated
solvent mixture,
decreasing the temperature of the solvent mixture, or freeze drying the
solvent mixture.
[0082] In the present invention, crystallization may be done with or without
crystal seed. The
crystal seed may come from any previous batch of the desired crystalline form.
The addition of
crystal seed may not affect the preparation of the crystalline forms in the
present invention.
[0083] The sample was recovered after completion of the isotherm and re-
analyzed by XRPD.
ABBREVIATIONS and ACRONYMS
Category Abbreviations
Full Name/Description
DSC
Differential Scanning C.alorimetry
DVS
Dynamic Vapor Sorption
NMR
Nuclear Magnetic Resonance
PLM
Polarized light microscopy
Analytical TGA
Thermogravimetric Analysis
XRPD
X-ray Powder Diffraction
Techniques VT-XRPD Variable
Temperature X-ray Powder Diffraction
ACN
Acetonitrile
CHCI3
Chloroform
DMF
Dimethylforamide
DMSO
Dimethylsulfoxide
Et0Ac
Ethyl acetate
Et0H
Ethanol
IPA
Isopropyl alcohol
MEK
Methyl ethyl ketone
Solvent Me0H
Methanol
MTBE
Methyl-ten-butyl ether
THF
Tetrahydrofuran
Other RT
Room temperature
v/v
percent volume ratio
CA 03150267 2022-3-5
WO 2021/050580
PCT/US2020/049986
[0084] The following Examples are intended to illustrate further certain
embodiments of the
invention and are not intended to limit the scope of the invention.
EXA1VIPLE 1
Preparation of N-(3-fluoro-4-02-(5-(((2-methoxyethyl)amino)methyl)pyridin-2-
yl)thieno[3,2-b]pyridin-7-yl)oxy)pheny1)-N-(4-fluorophenyl)cyclopropane-1,1-
dicarboxamide (Compound 1)
[0085] This Example illustrates the preparation of N-(3-fluoro-442-(5-(((2-
methoxyethyl)amino)methyl)pyridin-2-yOthieno[3,2-b]pyridin-7-y0oxy)pheny1)-N-
(4-
fluorophenyl)cyclopropane-1,1-dicarboxamide (Compound 1).
[0086] Step 1: N((6-bromopyridin-3-yOmethyl)-2-methoxyethan-1-amine (Compound
1A)
/-0¨Br
Me
Compound 1A
[0087] To a stirred solution of 2-Methoxyethylamine (3.0 eq) in
dichloromethane (DCM) (12
vol) was added Molecular sieves (0.3 w/w) and stirred for 2 hours at 25+5 C
under nitrogen
atmosphere. The reaction mass water content was monitored by Karl Fischer
analysis until the
water content limit reached 0.5 % w/w. Once the water content limit was
reached, the reaction
mass cooled to 5+5 C and 6-bromonicotinaldehyde (1.0 eq) was added lot wise
over period of 30
minutes to the above reaction mass at 5+5 C. The reaction mass was stirred for
30+5 minutes at
5+5 C and acetic acid (1_05 eq) was added drop wise at 5+5 C. After completion
of the addition,
the mass was slowly warmed to 25+5 C and stirred for 8 h to afford Compound
1A. The imine
formation was monitored by HPLC.
[0088] Step 2: tert-butyl ((6-bromopyridin-3-yOmethyl)(2-methoxyethypcarbamate
(Compound
1B)
16
CA 03150267 2022-3-5
WO 2021/050580
PCT/US2020/049986
CS¨Br
j¨NBoe
Me
Th
Compound 16
[0089] Charged Compoud 1A (1.0 eq) in THE (5.0 vol) was added and the reaction
mass was
stirred for 30 minutes at 25 5 C under nitrogen atmosphere. The reaction mass
was cooled to
temperature of about 10+5 C. Di-tert-butyl dicarbonate (1.2 eq) was added to
the reaction mass
at 10 5 C under nitrogen atmosphere and the reaction mass temperature was
raised to 25 5 C
and the reaction mass for about 2 hours. The progress of the reaction was
monitored by HPLC.
After ]PC completion, a prepared solution of Taurine (1.5 eq) in 2M aq NaOH
(3.1 vol) was
charged and stirred at 10 5 C for 16 h to 18 h. The reaction mass was further
diluted with 1M
aq.NaOH solution (3.7 vol) and the layers were separated. The aqueous layer
was extracted with
DCM (2 x 4.7vo1) and the extract combined with the organic layer. The combined
organic layers
were washed with 1M aq.NaOH solution (3.94 vol), followed by water (2x4.4
vol), and dried
over sodium sulfate (2.0 w/w) . The filtrate was concentrated under reduced
pressure below 40
C until no distillate was observed. Tetrahydrofuran (THE) was sequentially
added (1x4 vol and
lx 6vol) and concentrated under reduced pressure below 40 C until no
distillate was observed to
obtained Compound 1B as light yellow colored syrup liquid.
[0090] Step 3: tert-butyl 06-(7-chlorothieno[3,2-b]pyridin-2-yppyridin-3-
yl)methyl)(2-
methoxyethyl)carbamate (Compound 1C)
GI
/ __________________________________________________________________ (
S
j¨NBoc ¨N
Me
Compound 1C
[0091] To a stirred solution of 7-chlorothieno[3,2-14pyridine (1.05 eq) in
tetrahydrofuran (7 vol)
was added n-butyl lithium (2.5 M in hexane) drop wise at -15 10 C and stirred
for 90 minutes at
same temperature under nitrogen atmosphere. Zinc chloride (1.05 eq) was added
to the reaction
mass at -15+10 C. The reaction mass was slowly warmed to 25+5 C and stirred
for 45 minutes
under nitrogen atmosphere to afford Compound 1C. The progress of the reaction
was monitored
by HPLC.
17
CA 03150267 2022-3-5
WO 2021/050580
PCT/US2020/049986
[0092] Step 4: tert-butyl ((6-(7-(4-amino-2-fluorophenoxy)thieno[3.2-b]pyridin-
2-yl)pyridi11-3-
v1)methyl)(2-methoxyethyl)carbamate (Compound 1D)
an NH2
0 7
_________________________________________________________________________ s F
\ I
Me0-11-43 :\¨N
Compound ID
[0093] 3-fluoro-4-hydroxybenzenaminium chloride (1.2 eq) in DMS0 (3.9 vol) at
25 5 C was
charged under nitrogen atmosphere and the reaction mass was stirred until
observance of a clear
solution at 25 5 C. t-BuOK was added lot wise under nitrogen atmosphere at 25
10 C. The
reaction mass temperature was raised to 45 5 C and maintained for 30 minutes
under nitrogen
atmosphere. Compound 1C was charged lot-wise under nitrogen atmosphere at 45 5
C and
stirred for 10 minutes at 45 5 C.The reaction mixture was heated to 100th 5 C
and stirred for 2
hrs. The reaction mass is monitored by HPLC.
[0094] After reaction completion, the reaction mass was cooled to 10- 5 C and
quenched with
chilled water (20 vol) at 10 5 C. The mass temperature was raised to 25th 5 C
and stirred for 7-8
h. The resulting Compound 1D crude was collected by filtration and washed with
2 vol of water.
Crude Compound 1D material taken in water (10 vol) and stirred for up to 20
minutes at 25 5 C.
The reaction mass was heated to 45 5 C and stirred for 2-3 h at 45 5 C,
filtered and vacuum-
dried.
[0095] Crude Compound 1D was taken in MTBE (5 vol) at 25 5 C and stirred for
about 20
minutes at 25 5 C. The reaction mass temperature was raised to 45 5 C, stirred
for 3-4 h at
45th5 C and then cooled to 20th5 C. The reaction mass was stirred for about 20
minutes at
20 5 C, filtered, followed by bed wash with water (0. 5 vol) and vacuum-dried.
[0096] The crude material was dissolved in acetone (10 vol) at 25 5 C and
stirred for about 2h
at 25 5 C. The reaction mass was filtered through a celite bed and washed with
acetone (2.5
vol). The filtrate was slowly diluted with water (15 vol) at 25th5 C. The
reaction mass was
18
CA 03150267 2022-3-5
WO 2021/050580
PCT/US2020/049986
stirred for 2-3 h at 25+5 C, filtered and bed washed with water (2 vol) &
vacuum-dried to afford
Compound 1D as brown solid.
[0097] Step 5: 1-04-42-(5-(((tert-butoxycarbony1X2-
methoxyethyDamino)methyl)pyridin-2-
y1)thieno[3,2-b]pyridin-7-yl)oxy)-3-fluorophenyl)carbamoyl)cyclopropane-1-
carboxylic acid
(Compound 1E)
F NINON
0 0
0
/
N
Me
Compound 1 E
[0098] To a solution of Compound 1D (1.0 eq.) in tetrahydrofuran (7 vol.),
aqueous potassium
carbonate (1.0 eq.) in water (8 vol.) was added. The solution was cooled to
5+5 C, and stirred
for about 60 min. While stirring, separately triethylamine (2.0 eq.) was added
to a solution of
1,1-cyclopropanedicarboxylic acid (2.0 eq.) in tetrahydrofuran (8 vol.), at
5+5 C, followed by
thionyl chloride (2.0 eq.) and stirred for about 60 min. The acid chloride
mass was slowly added
to the Compound 10 solution at 5+5 C. The temperature was raised to 25+5 C and
stirred for
3.0 h. The reaction was monitored by HPLC analysis.
[0099] After reaction completion, the mass was diluted with ethyl acetate (5.8
vol.), water (5.1
vol.), 10% (w/w) aqueous hydrochloric acid solution (0.8 vol.) and 25% (w/w)
aqueous sodium
chloride solution (2 vol.). The aqueous layer was separated and extracted with
ethyl acetate (2 x
vol.). The combined organic layers were washed with a 0.5M aqueous sodium
bicarbonate
solution (7.5 vol.). The organic layer was treated with Darco activated
charcoal (0.5 w/w) and
sodium sulfate (0.3 w/w) at 25+5 C for 1.0 h. The organic layer was filtered
through celite and
washed with tetrahydofuran (5.0 vol.). The filtrate was concentrated under
vacuum below 50 C
to about 3 vol and co-distilled with ethyl acetate (2 x 5 vol.) under vacuum
below 50 C up to ¨
3.0 vol. The organic layer was cooled to 15+5 C, stirred for about 60 min.,
filtered, and the solid
was washed with ethyl acetate (2.0 vol.). The material was dried under vacuum
at 40+5 C until
water content was less than 1% to afford Compound 1E as brown solid.
19
CA 03150267 2022-3-5
WO 2021/050580
PCT/US2020/049986
[00100] Step 6: tert-butyl ((6-(7-(2-fluoro-4-0-((4-
fluorophenyl)carbamoyl)cyclopropane-
l-carboxamido)phenoxy)thieno[3,2-b]pyridin-2-yppyridin-3-y1)methyl)(2-
methoxyethyl)carbamate (Compound 1F)
H.iyir
.N
6 o
NCBoc N \S )
j¨C/1
Me
Compound "IF
[00101] Pyridine (1.1 eq.) was added to a suspension of
Compound 1E (1.0 eq.) in
tetrahydrofuran (10 vol.) and cooled to 5th5 C. Thionyl chloride (2.0 eq.) was
added and stirred
for about 60 min. The resulting acid chloride formation was confirmed by HPLC
analysis after
quenching the sample in methanol. Separately, aqueous potassium carbonate (2.5
eq.) solution
(7.0 vol. of water) was added to a solution of 4-fluoroaniline (3.5 eq.) in
tetrahydrofuran (10
vol.), cooled to 5th5 C, and stirred for about 60 min. The temperature of the
acid chloride mass at
5 C was raised to a temperature of about 25 5 C and stirred for 3 h. The
reaction monitored
by HPLC analysis.
[00102] After completion of the reaction, the solution
was diluted with ethyl acetate (25
vol.), the organic layer was separated and washed with a 1M aqueous sodium
hydroxide solution
(7.5 vol.), a 1M aqueous hydrochloric acid solution (7.5 vol.), and a 25%
(w/w) aqueous sodium
chloride solution (7.5 vol.). The organic layer was dried and and filtered
with sodium sulfate (1.0
w/w). The filtrate was concentrated ¨ 3 vol under vacuum below 50 C and co-
distilled with
ethyl acetate (3 x 5 vol.) under vacuum below 50 C to ¨ 3.0 vol. Ethyl acetate
(5 vol.) and
MTBE (10 vol.) were charged, heated up to 50 5 C and stirred for 30-60 min.
The mixture was
cooled to 15th5 C, stirred for about 30 min., filtered, and the solid was
washed with ethyl acetate
(2.0 vol.). MGB3 content was analyzed by HPLC analysis. The material was dried
under vacuum
at 40 5 C until the water content reached about 3.0% to afford Compound 1F as
brown solid.
CA 03150267 2022-3-5
WO 2021/050580
PCT/US2020/049986
[00103] Step 7: N-(3-fluoro-4-02-(5-(((2-
methoxyethypamino)methyppyridin-2-
vDthieno[3,2-b]pyridin-7-y0oxy)pheny1)-N-(4-fluorophenyl)cyclopropane-1,1-
dicarboxamide
(Compound 1)
H
F soi
110 N N
0 0
CC S
Me0-f
Compound "I
[0100] To a mixture of Compound 1F in glacial acetic acid (3.5 vol.)
concentrated hydrochloric
acid (0.5 vol.) was added and stirred at 25 5 C for 1.0 h. The reaction was
monitored by HPLC
analysis.
[0101] After reaction completion, the mass was added to water (11 vol.) and
stirred for 20 5 C
for 30 min. The pH was adjusted to 3.0 th 0.5 using 10% (w/w) aqueous sodium
bicarbonate
solution and stirred for 20 5 C for approximately 3.0 h.. The mass was
filtered, washed with
water (4 x 5.0 vol.) and the pH of filtrate was checked after every wash. The
material was dried
under vacuum at 50 5 C until water content was about 10%.
[0102] Crude Compound 1 was taken in ethyl acetate (30 vol.), heated to 70 10
C, stirred for
1.0 h., cooled to 25 5 C, filtered, and washed with ethyl acetate (2 vol.).
The material was dries
under vacuum at 45 5 C for 6.0 h.
[0103] Crude Compound 1 was taken in polish filtered tetrahydrofuran (30 vol.)
and pre-
washed Amberlyst A-21 Ion exchange resin and stirred at 25th5 C until the
solution became
clear. After getting the clear solution, the resin was filtered and washed
with polish filtered
tetrahydrofuran (15 vol.). The filtrate was concentrated by ¨50% under vacuum
below 50 C and
co-distilled with polish filtered IPA (3 x 15.0 vol.) and concentrated up to
¨50% under vacuum
below 50 C. Charged polish filtered IPA (15 vol.) was added and the solution
concentrated
under vacuum below 50 C to ¨ 20 vol. The reaction mass was heated to 80 5 C,
stirred for 60
min. and cooled to 25th5 C. The resultant reaction mass was stirred for about
20 hours at
25th5 C. The reaction mass was cooled to 0th5 C, stirred for 4-5 hours,
filtered, and washed with
polish filtered IPA (2 vol.). The material was dried under vacuum at 45 5 C,
until the water
21
CA 03150267 2022-3-5
WO 2021/050580
PCT/US2020/049986
content was about 2%, to obtain the desired product Compound 1_ 111-NMR (400
MHz,
DMSO-d6): 610.40 (s,111), 10.01 (s, 1H), 8.59¨ 8.55 (m, 1H), 8.53 (d, J= 5.6
Hz, 1H), 8.32 (s,
111), 8.23 (d, J= 8.0 Hz, 111), 7.96 ¨ 7.86 (m, 211), 7/0 ¨ 7_60 (m, 211),
7_56 ¨ 7_43 (m, 211),
7.20 ¨ 7.11 (m, 2H), 6.66 (d, 3= 5.6 flz, 1H), 3.78 (s, 2H), 3.41 (t, J= 5.6
Hz, 2H), 3.25 (s, 3H),
2.66 (t, J= 5.6 Hz, 2H), 1.48 (s, 4H)ppm. MS: M/e 630 (M-1-1)+.
EXAMPLE 2
Preparation of Crystalline Form D of N-(3-fluoro-4-((2-(5-(02-
methoxyethyl)amino)methyl)pyridin-2-y1)thienop,2-b]pyridin-7-ypoxy)pheny1)-N-
(4-
11uorophenyl)eyelopropane-1,1-dicarboxamide
EXAMPLE 2A: Preparation of Compound 1 Crystalline Form D
[0104] To a 50 L reactor, 7.15 Kg of Compound 1, 40 g of Form D as crystal
seed and 21 L
acetone 99%) were added. The mixture was heated to reflux ( ¨56 C) for 1-2 h.
The mixture
was agitated with an internal temperature of 205 C for at least 24 h. Then,
the suspension was
filtered and washed the filter cake with 7 L acetone. The wet cake was dried
under vacuum at
C, to obtain 5.33 kg of Compound 1 of desired Form D
[0105] X-Ray Powder Diffraction (XRPD)
The XRPD patterns were collected with a PAN alytical X' Pert PRO IVIPD
diffractometer using
auincident beam of Cu radiation produced using au Optix long, fine-focus
source. An elliptically
graded multilayer mirror was used to focus Cu Ka X -rays through the specimens
and
onto the detector. Prior to the analysis, a silicon specimen (NIST SRM 640e)
was analyzed to
verify the observed position of the Si Ill peak is consistent with the NIST-
certified position. A
specimen of each sample was sandwiched between 3- m-thick films and analyzed
in
transmission geometly. A beam-stop, short autiscatter extension, and an
autiscatter knife edge
were used to minimize the background generated by air. Soller slits for the
incident aud
diffracted beau is were used to minimize broadening from axial divergence. The
diffraction
patterns were collected using a scanning position-sensitive detector
(X'Celerator) located 240
22
CA 03150267 2022-3-5
WO 2021/050580
PCT/US2020/049986
mm from the specimens and Data Collector software v. 2.26. Pattern Match
v2.3.6 was used to
create XRPD patterns.
[0106] The X-ray powder diffraction (XRPD) pattern was used to characterize
the Compound 1
obtained, which showed that the Compound 1 was in Crystalline Form D of
Compound 1
(Compound 1 Form D), see Figure 1A. The XRPD pattern yielded is substantially
the same as
that shown in Figure 3C.
[0107] Differential Scanning Calorimetry (DSC)
[0108] DSC was performed using a Mettler-Toledo DSC3+ differential scanning
calorimeter.
Temperature calibration was performed using octane, phenyl salicylate, indium,
tin, and zinc.
The TAWN sensitivity was 11.9. The samples were placed into aluminum DSC pans,
covered
with lids, and the weights were accurately recorded. A weighed aluminum pan
configured as the
sample pan was placed on the reference side of the cell. The pan lids were
pierced prior to
sample analyses. The method name on the therrnograms is an abbreviation for
the start and end
temperature as well as the heating rate; e.g., -30-250-10 means "from ambient
to 250 C, at
C/min." The nitrogen flow rate was 50.0 mIlmin. This instrument does not
provide gas
pressure value as required by USP because it is the same as atmospheric
pressure.
[0109] A broad small endotherm with a peak maximum at approximately 57 C to 62
C (onset
¨20 C to 22 C) followed by a sharp endotherni with a peak maximum at
approximately 180 C
(onset -478 C) were observed. These events could be due to the loss of
volatiles and a melt,
respectively (see Figure 1B).
[0110] In an alternative embodiment, Form D was prepared as follows.
Designated Material 0
was suspended in 600 IS of acetone. Initial dissolution was observed followed
by re-
precipitation. The amount of suspended solids was not measured, because the
target of the
experiment was to get a suspension with enough solids to slurry, isolate and
collect XRPD data.
Based on the solubility of Form D in acetone, a very rough estimate for the
scale of the
experiment is about 80-100mg. The suspension was stirred at ambient
temperature for
approximately 2.5 weeks, after which the solids were isolated by
centrifugation with filtration.
XRPD data appeared to be consistent with Form a The sample was then dried in
vacuum oven
at ¨40 C for --2.5 hours. The XRPD pattern of the final solids was consistent
with Form D.
23
CA 03150267 2022-3-5
WO 2021/050580
PCT/US2020/049986
EXAMPLE 2B: Preparation of Compound 1 Form D
[0111] 427.0 mg of Compound 1 was dissolved in 5 mL of TI-IF to obtain a clear
brown
solution. The resulting solution was filtered, and the filtrate evaporated
under flow of nitrogen.
A sticky solid was obtained, which was dried under vacuum in room temperature
for ¨5 min, still
a sticky brown solid obtained. It was dissolved in 0.2 mL of Et0Ac and
sonicated to dissolve.
The solution obtained was stirred at room temperature for 15 min and a solid
precipitated. The
resulting solid was added 0.4 mL of Et0Ac and stirred in room temperature for
21 h. 40 min to
ontian a suspension. The solid was spparated from mother liquor by
centrifugation, then the
resulting solid was resuspended the in 0.6 mL of Et0Ac and stirred in room
temperature for 2
days. The solid was isolated by centrifugation, to obtain Compound 1 of
desired Form D.
[0112] The X-ray powder diffraction (XRPD) pattern was used to characterize
the Compound 1
obtained, which showed that the Compound 1 was in Crystalline Form D of
Compound 1
(Compound 1 Form D).
EXAMPLE 2C: Preparation of Compound 1 Form D
[0113] Single crystal X-ray diffraction data of Compound 1 was collected at
180 K on a Rigaku
XtaLAB PRO 007HF(Mo) diffractometer, with Mo Ka radiation (k= 0.71073 A). Data
reduction and empirical absorption correction were performed using the
CrysAlisPro program.
The structure was solved by a dual-space algorithm using SHELXT program. All
non-hydrogen
atoms could be located directly from the difference Fourier maps. Framework
hydrogen atoms
were placed geometrically and constrained using the riding model to the parent
atoms. Final
structure refinement was done using the SHELXL program by minimizing the sum
of squared
deviations of F2 using a full-matrix technique.
Preparation of Compound I Form D (a Single Oystal)
[0114] Compound 1 Form D was dissolved in a mixture of acetone/ACN (1/2) with
the
concentration of Compound 1 at ¨7 mg/mL. A block single crystal was obtained,
which was a
single crystal.
[0115] The XRPD pattern was used to characterize the single crystal of
Compound 1 Form D
obtained, see Figure 2A. The crystal structural data are summarized in Table
1B. The refined
24
CA 03150267 2022-3-5
WO 2021/050580
PCT/US2020/049986
single crystal structure were shown in Figure 2B. The single crystal structure
of Compound 1
Form D is in the P-1 space group and the triclinic crystal system. The
terminal long alkyl chain
is found to have large ellipsoids, indicating high mobility with disordered
atoms.
[0116] The theoretical XRPD calculated from the single crystal structure and
experimental
XRPD are essentially similar (Figure 2A). A few small peaks are absent or
shift because of
orientation preference, disorder and tested temperature (180 K for single
crystal data and 293 K
for experimental one).
[0117] Table 1B. Crystal Data and Structure Refinement for Compound 1 Form D
(a
Single Crystal)
Empirical formula
C33H29F2N504S
Formula weight
629.67
Temperature/K
179.99(10)
Crystal system
triclinic
Space group
P-1
a/A
9.4563(5)
b/A
12.3432(5)
14.4775(6)
a?
67.575(4)
fiP
83.080(4)
80.099(4)
Volume/A3
1535.98(13)
2
pcatcg/cm3
1.361
p/mm-1
0.164
F(000)
656.0
Crystal size/mm3
0.22 x 0.16 x 0.12
Radiation
Mo Ka (A = 0.71073)
20 range for data collection?
5.184 to 54.958
CA 03150267 2022-3-5
WO 2021/050580
PCT/US2020/049986
Index ranges
_
5 _
Reflections collected 19644
Independent reflections
7025 [Rini = 0.0232, Rsigma = 0.0321]
Data/restraints/parameters
7025/312/442
Goodness-of-fit on F2 1.036
Final R indexes [I>=2o- (I)]
Ri = 0.0587, -wR2 = 0.1494
Final R indexes [all data]
RI = 0.0780, -wR2 = 0.1599
Largest diff. peak/hole / e 2t3
0.96/-0.45
EXAMPLE 3
Solid Screen of N-(3-fluoro-44(2-(5-(((2-methoxyethyl)amino)methyl)pyridin-2-
yl)thieno[3,2-b]pyridin-7-y1)oxy)pheny1)-N-(4-fluorophenyl)cyclopropane-1,1-
dicarboxamide (Compound 1)
[0118] A solid form screen of Compound 1 was conducted. Solids, when isolated
in sufficient
amounts, were characterized by X-ray powder diffraction (XRPD) pattern. The
XRPD patterns
were compared to each. Furthermore, other spectrum or methods, such as
differential scanning
calorimetry (DSC), thermogravimetry (TGA), and dynamic vapor sorption (DVS),
were used to
characterize or investigate the solids obtained.
[0119] X-Ray Powder Diffraction (XRPD)
[0120] Pattern Match versions 2.16 and 3Ø4 were used to create the XRPD
pattern overlays.
Figures labeled "Image by PatternMatch v3Ø4" were generated using an
unvalidated version of
the software and are therefore considered non-cGMP representations.
1) Transmission Mode XRPD
[0121] XRPD patterns were collected with a PANalytical )(Pert PRO MPD
diffractometer
using an incident beam of Cu radiation produced using an Optix long, fine-
focus source. An
elliptically graded multilayer minor was used to focus Cu Ka X-ray radiation
through the
specimen and onto the detector. Prior to the analysis, a silicon specimen
(NIST SRM 640d) was
analyzed to verify the observed position of the Si (111) peak is consistent
with the NIST-
certified position. A specimen of the sample was sandwiched between 3- m-thick
films and
26
CA 03150267 2022-3-5
WO 2021/050580
PCT/US2020/049986
analyzed in transmission geometry. A beam-stop, short antiscatter extension,
and antiscatter
knife edge, were used to minimize the background generated by air. Soifer
slits for the incident
and diffracted beams were used to minimize broadening from axial divergence.
Diffraction
patterns were collected using a scanning position-sensitive detector
(Xtelerator) located 240
mm from the specimen and Data Collector software v. 2.2b.
2) Reflection Mode ,3112PD
[0122] VT-XRPD patterns were collected with a PANalytical X'Pert PRO MPD
diffractometer
using an incident beam of Cu Ka radiation produced using a long, fine-focus
source and a nickel
filter. The diffractometer was configured using the symmetric Bragg¨Brentano
geometry. Data
were collected and analyzed using Data Collector software v. 2.2b. Prior to
the analysis, a silicon
specimen (NIST SRM 640d) was analyzed to verify the observed position of the
Si (111) peak is
consistent with the NIST-certified position. A specimen of the sample was
packing in a nickel-
coated copper well. Antiscatter slits (SS) were used to minimize the
background generated by
air. Soller slits for the incident and diffracted beams were used to minimize
broadening from
axial divergence. Diffraction patterns were collected using a scanning
position-sensitive detector
(X'Celerator) located 240 mm from the sample and Data Collector software v.
2.2b.
3) Variable Temperature ARM
[0123] An Anton Paar temperature-humidity chamber (THC) was used to collect in-
situ
reflection-mode XRPD patterns as a function of temperature. The temperature of
the specimen
was changed with a Peltier thermoelectric device located directly under the
specimen holder and
monitored with a platinum-100 resistance sensor located in the specimen
holder. The
thermoelectric device was powered and controlled by an Anton Paar TCU 50
interfaced with
Data Collector.
Polarized Light Microscopy (PLM)
[0124] Samples were observed using a Leica M712.5 stereomicroscope with a
first order red
compensator. Various objectives typically ranging from 0.8-10x were used with
crossed-
polarized light to view the samples. Selected samples were observed in mineral
oil. Selected
samples were analyzed using a Leica DM LP microscope equipped with a SPOT
Insight!: color
digital camera. Each sample was placed on a glass slide, a cover glass was
placed over the
27
CA 03150267 2022-3-5
WO 2021/050580
PCT/US2020/049986
sample, and a drop of mineral oil was added to cover the sample by
capillarity. Each sample was
observed using a 20x 0.40NA and 40x 0.74NA magnification with crossed
polarizers and a first
order red compensator. Images were captured using SPOT software (v. 4.5.9). A
micron bar was
inserted onto each image as a reference for particle size.
Differential Scanning Calorimetry (DSC)
[0125] DSC analyses were performed using a TA Instruments 2920 and Q2000
differential
scanning calorimeters Temperature calibration was performed using NIST-
traceable indium
metal. The sample was placed into an aluminum DSC pan, covered with a lid, and
the weight
was accurately recorded. A weighed aluminum pan, TOC or TOCHSMP, (Tzero
crimped or Tzero
hermetically sealed with manual pin hole pans, respectively) configured as the
sample pan was
placed on the reference side of the cell. The method code on the thenmogram is
an abbreviation
for the start and end temperature as well as the heating rate; e.g., - 30-250-
10 means "from ¨30
C to 250 C, at 10 C/min."
Thermogravimetry (TGA)
[0126] TG analyses were performed using a TA Instruments 2950
thermogravimetric analyzer.
Temperature calibration was performed using nickel and Alumerm. Each sample
was placed in
an aluminum pan and inserted into the TG furnace. The furnace was heated under
a nitrogen
purge. The method code on the thermogram is an abbreviation for the start and
end temperature
as well as the heating rate; e.g., 25-350-10 means "from 25 'V to 350 C, at
10 C/min".
Dynamic Vapor Sorption (DVS)
[0127] Automated vapor sorption (VS) data were collected on a VTI SGA-100
Vapor Sorption
Analyzer. NaCl and PVP were used as calibration standards. Samples were not
dried prior to
analysis. Sorption and desorption data were collected over a range from 5% to
95% RH at 10%
RH increments under a nitrogen purge. The equilibrium criterion used for
analysis was less than
0.0100% weight change in 5 minutes with a maximum equilibration time of 3
hours. Data were
not corrected for the initial moisture content of the samples.
Indexing
28
CA 03150267 2022-3-5
WO 2021/050580
PCT/US2020/049986
[0128] Computational studies, i.e. indexing and structure refinement are
performed under the
"Procedures for SSCI Non-cGMP Activities." Agreement between allowed peak
positions and
observed peaks indicates a consistent unit cell determination. Indexing was
performed using
X'Pert High Score Plus 2.2a (2.2.1) and proprietary SSCI software. No attempts
at molecular
packing were performed to confirm tentative indexing solutions within the
scope of this work.
Example 3A: Preparation of Matereial A. Material B (containing Material 071,
Material 0
of Compound 1
[0129] The XRPD patterns of Matereials A, B (containing Material 0 and
Material 0 of
Compound 1 observed are given in Figure 3G.
Example 3B: Stable Form Screen of Compound 1
[0130] Material B (containing Material 0) of Compound 1 obtained in Example 3A
was
triturated in various solvents including solvent systems with high water
activity to target
potential hydrates_ The experiments were mostly conducted at ambient
temperature. Selected
experiments were carried out at ¨40 'V to achieve sufficient solubility. In an
attempt to change
the impurity profile of Compound 1, the majority of slurries were filtered
after approximately
24 hours and the solvents were replaced with fresh solvents (ratios were
adjusted if needed). The
resulting slurries were triturated for up to ¨2.5 weeks. Conditions and
results of the stable form
screen are summarized in Table 2A.
Table 2A. Stable Form Screen of Compound 1
Solvent, conditions (a) Observations
XRPD Results
(vv)
Acetone, RT (b) Unknown morphology, agglomerates, some
Birefringence with Form D
extinction
ACN, RT Unknown morphology, agglomerates, no
Birefringence with Form D
extinction
CHC13/MTBE (50/50), RT Unknown morphology, agglomerates, some Birefringence
with Form D
extinction
Dioxane, RT Unknown morphology, agglomerates, no
Birefringence with Form C
extinction
DMF/ACN (30/70), RT (b) Unknown morphology, agglomerates, some Birefringence
with Form D
extinction
Et0Ac, RT (b) Unknown morphology, agglomerates, no
Birefringence with Form C
extinction
29
CA 03150267 2022-3-5
WO 2021/050580
PCT/US2020/049986
Et0H, RT Unknown morphology, agglomerates, no
Birefringence with Form D
extinction
IPA, ¨40 t(c) Unknown morphology, agglomerates, some
Birefringence with Form D
extinction
MEIC/heptane (80/20), RT Unknown morphology, agglomerates, some Birefringence
with Form C
(b) extinction
Me0H/CHC13 (90/10), RT Unknown morphology, agglomerates, some Birefringence
with Form 11
(b) extinction
Me011/THF (80/20), RT Unknown morphology, agglomerates, no Birefringence with
Form 11
(b) extinction
Nitromethane, RT Unknown morphology, agglomerates, no
Birefringence with Form D
extinction
Toluene/THF (60/40), RT Unknown morphology, agglomerates, some Birefringence
with Form C
(b) extinction
Acetone/water (80/20), RT Unknown morphology, agglomerates, some Birefringence
with Materials F + G
(b) extinction
Dioxane/water (80/20), RT Dissolution, clear
DMF/watcr (70/30), RT (b) Unknown morphology, agglomerates, some Birefringence
with Material G, likely
extinction
contains F
THF/water (40/60), RT (b) Unknown morphology, agglomerates, no Birefringence
with Materials F + G
extinction
Water, ¨40 C Unknown morphology, agglomerates, no
Birefringence with Materials F + I
extinction
(a) Trituration was performed for ¨2.5 week with solvent replacement,
unless otherwise indicated_
(b) Dissolution was observed at solvent addition, which followed by
precipitation.
(c) Trituration was conducted for -2 weeks, without solvent replacement.
(d) Solubility was determined gravimetrically using mother liquor
solutions.
(e) Samples appeared as film, oil orglass.
Example 3C: Polvmorph Screen of Compound 1 (Solution Methods)
[0131] Material B (containing Material 0) obtained in Example 3A of Compound 1
was
subjected to various solution crystallization techniques such as evaporations,
vapor diffusion,
cooling to ambient or subambient temperature, slurries, as well as
solvent/antisolvent
precipitation aiming at the formation of metastable forms. Both, non-aqueous
solvents and
solvent systems with high water activity were employed. Conditions and results
of the
polymorph screen (solution experiments) are summarized in Table 2B.
CA 03150267 2022-3-5
WO 2021/050580
PCT/US2020/049986
Table 2B. Polymorph Screen of Compound 1 (Solution Methods)
Solvent system Conditions (a)
Observation XRPD Results
(v/v)
Acetone Slow evaporation
Unknown moiphology, some Material K,
Birefringence with extinction similar to Material
Acetone/MTBE Vapor diffusion attempt
No solids
ACN Slow cooling from 55 C to RT then -25 Small needles,
agglomerates, Material L,
Cto -10 C.
Birefringence with extinction disordered
CHC13 Slow evaporation
Film
Solvent/antisolvent precipitation attempt (no
CHC13/1PA solids). Cooling to -25 C to -10 C.
Clear
Solvent/antisolvent precipitation attempt (no
Film
solids). Cooling to -25 C to -10 C.
Fast evaporation.
Dioxane Fast cooling from 55 C to RT
Clear
Dioxane/hentane Added heptane, cooling to 2-8 C.
Clear
(63/37)
Forms C + D
Diosane/heptane Added heptane (oiled out then
Unknown morphology, opaque
(38/62) precipitation). Slurring at RT for 4 days.
aggregates, some Birefringence
with extinction
Et0Ac Slow cooling attempt from 70 C to RT then
-25 C to - 10 C
Clear, no solids
Et0H Slow cooling from 55 C to RT then -25 et Very small, possibly
needles,
to -10 C.
agglomerates, Birefringence Material J
with extinction
WA Slow cooling from 70 C to RT then -25 C Rosette-like, some
Birefringence Materials E + G,
to -10 C.
with extinction disordered
MEK Slow cooling from 55 C to RT then -25 C Clear
to -10 C.
The clear solution of Material B (containing Unknown morphology, opaque
MEK/heptane Material 0) disolved in MEK. Added
aggregates, some BE Form D
(33/67) heptane (oiled out the precipitation).
Slurring at RT for 4 days.
Unknown morphology, possibly
Me0H/CHC13
needle- like, agglomerates,
(50/50) Fast evaporation
Birefringence with extinction Material J
Nitromethane Slow cooling from 70 C to RT, then -25 'V Rosettes, Birefringence
with Form D (shifted)
to -10 C.
extinction
Vapor diffusion attempt (oiled out). Added Unknown morphology, opaque
THF/MTBE MTBE. Stirring at RT for 4 days.
aggregates, some Birefringence Form C
with extinction
31
CA 03150267 2022-3-5
WO 2021/050580
PCT/US2020/049986
Unknown morphology,
Acetone/water Solvent/antisolvent precipitation
agglomerates, some Material F
Birefringence with extinction
ACN/water (57/43) Slow cooling from 70 C to RT (oil initially Small needles,
agglomerates,
formed dissolved) then 2-8 C.
Birefringence with extinction Material F
Slow cooling from 70 C to RT (oiled out).
Unknown morphology,
ACN/water (33/67) Sonicated fro 20 min. Slurring at RT for2
agglomerates, no
Birefringence Materials F + G
weeks,
with extinction
Dioxane/water Slow cooling from 70 C to RT then 2-8 C
(20/80) (some oiling out).
Insufficient solids
(a) Solvent ratios, temperature and duration of
experiments are approximate.
[0132] Material J was produced under selected, both aqueous and non-aqueous
conditions.
Material J is crystalline. Short term vacuum drying at ¨40 C resulted in the
presence of another
material (designated Material M).
Example 3C: Drvinz experiments of Compound 1 Crvsatlline Froms
[0133] Limited non-solvent based experiments were conducted with materials
generated during
the stable form screen and included short term vacuum drying at
elevatedtemperature.
Conditions and results of the drying experiments are summarized in are shown
in Table 2C.
Table 2C. Non-Solvent Based Experiments
Starting Material
Conditions XRPD Results
Form C Vacuum oven drying,
¨40 C,2.5 Form C
Form D Vacuum oven drying,
¨40 C, 2.5 Form 1)
Form H Vacuum oven drying,
¨40 C, 2.5 Form H
Material J Vacuum oven drying,
¨40 C, 2.5 Materials J + M
Example 3D: X-ray powder diffraction (XRPD) pattern of Solid Forms of Compound
1
[0134] Several materials obtained in Example 3A through 3E, with unique XRPD
patterns were
produced. The unique materials were designated as Forms C, D, H, and Materials
A, B, E, F, G,
J, K, L, N and 0. The XRPD patterns of the forms are presented in Figure 3A.
The patterns of
other materials observed are given in Figure 3B.
32
CA 03150267 2022-3-5
WO 2021/050580
PCT/US2020/049986
[0135] Further successful indexing of the XRPD pattern for Form C (from
dioxane), Form D
and Form H indicates that Forms C, D and H are composed of a single
crystalline phase. See,
Figure 3B, Figure 3C and Figure 3D, separately. And, the TGA and DSC
Thermograms for
Form D produced in acetone was shown in Figure 3F.
[0136] The XRPD patterns of Materials A Through L could not be indexed,
indicatdes that
Materials A Through L are crystalline materials with some degree of disorder,
or mixtures. See,
Figure 3E Wherein, Material E was observed in a single experiment conducted in
isopropyl
alcohol, and the sample was produced by cooling and possibly contained another
material
designated Material G; Material F was produced at moderate and high water
activity often as a
mixture with another material designated as Material G; Material G, observed
as a mixture with
Material F, was only produced in solvent systems with higher water activities;
Material K has a
similar XRPD pattern to that of Material G.
Example 2E: Slurry Interconversion Experiments
[0137] To investigate the relationship between selected materials produced
during screening,
limited slurry interconversion experiments were conducted. The experiments
were performed by
slurring seeds of solids of interest at ambient temperature in two different
solvent systems. All
materials were vacuum dried prior to the slurry (-40 C, ¨2.5 hours). Solvent
conditions were
selected to achieve sufficient solubility of materials tested. Both, non-
aqueous conditions and a
solvent system with high water activity were utilized. Results are summarized
in Table 2D.
[0138] A slurry of Forms C, D, and H was conducted in ethyl acetate, and the
results were
inconclusive. The experiment led to a mixture of Forms C and D showing that
Form H is the
least thermodynamically stable under these conditions, but the relative
stability of C and D
remains unclear. The comparison of the XRPD peak intensities for the mixture
suggests possible
excess of Form C. However, this could be caused by Form H going selectively to
Form C.
Therefore, the relative stability of Forms C and D is not known The slurry of
seeds of Materials
F, G, and J in tetrahydrofuran/water (40/60) resulted in Material F
Table 2D. Slurry Interconversion Experiments
Starting Material (a) tAvent
System (b) XRPD Results
Form C+Form D + Form H tOAc
Forms C + D
33
CA 03150267 2022-3-5
WO 2021/050580
PCT/US2020/049986
Materials FIG mixture THF/water
(40/60) Material F
Materials NM mixture
(a) Slurries were performed for ¨42 hours with vacuum dried starting
material (-40 'CC, ¨2.5
hours).
(b) Solids were agitated in solvents saturated by slurry for ¨3 hours, with
solvent replacement for
ethyl acetate solution.
Example 2H: Preliminary Physical Stability Assessment of Form D
[0139] Preliminary physical stability assessment of Form D was performed. The
data are
summarized in Table 2E
[0140] The experiments indicated Form D remained unchanged when subjected to
¨43% and
¨75% RH stresses and a short term vacuum drying at ¨40 'C. The XRPD patterns
of the stressed
materials show no significant peak shifts compared to the untreated samples.
The XRPD pattern
of Form D obtained from high water activity slurry is consistent with the
pattern of the untreated
material. However, small shifts of selected peaks were observed, possibly due
to hydration.
Table 2E. Preliminary Stability Assessment for Form D
Conditions (a) XRPD Results
¨43% RH/RT Consistent with Form D, no significant shifts of peaks
75% RH/RT Consistent with Form I), no significant shifts of peaks
¨
Acetone/water (40/60), sluny, RT
Consistent with Form D, slight peak shifts
Et0HAvater (40/60), slurry, RT
Consistent with Form D, slight peak shifts
Water, slurry, RT
Consistent with Form D, slight peak shifts
[0141] While the invention has been described in connection with specific
embodiments thereof,
it will be understood that it is capable of further modifications and this
application is intended to
cover any variations, uses, or adaptations of the invention following, in
general, the principles of
the invention and including such departures from the present disclosure as
come within known or
customary practice within the art to which the invention pertains and as may
be applied to the
essential features hereinbefore set forth, and as follows in the scope of the
appended claims.
34
CA 03150267 2022-3-5
